Mechanistic insights into NB pathogenesis have propelled the development of novel compounds such as IBL-302 (BRD4-targeting PROTAC) and APG-115 (MDM2 degrader), which are currently undergoing Phase I/II clinical trials after producing breakthrough efficacy in MYCN-driven models. Here, MYCN is linked to neuroblastoma.